TIN convalescent plasma study by former GHUCCTS KL2 scholar Dr. Seble Kassaye featured on NBC4

Georgetown University Logo

Dr. Seble Kassaye, infectious disease expert at Georgetown University Medical Center and former GHUCCTS KL2 scholar, is the principal investigator for a local convalescent plasma COVID-19 clinical trial. Dr. Kassaye recently appeared on NBC4 Washington to discuss the trial.

This trial is led by Johns Hopkins University. MedStar Georgetown University Hospital, MedStar Washington Hospital Center, and Georgetown University Medical Center are serving as subsites for the trial, with support from GHUCCTS and the Trial Innovation Network (TIN). This study is for people at high risk of exposure to COVID-19, such as hospital personnel (clinical staff, environmental services, dining services, etc) or anyone who is caring for someone with COVID-19. This study will test whether an infusion of plasma containing antibodies from persons who have recovered from COVID-19 can prevent others from getting it.

Publishing CTSA Program Hub’s Name
CTSA Program In Action Goals
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials